Ku EJ, Yoo WS, Lee EK, et al. - Researchers conducted this systematic review and meta-analysis to determine the impact of thyrotropin (TSH) suppression therapy on bone mineral density (BMD) in differentiated thyroid cancer (DTC) patients. PubMed, Embase, the Cochrane library, and other sources were searched. DTC patients who received TSH suppression therapy and had their BMD measured were eligible for observational studies. For quantitative analysis, 17 studies were involved. Participants in the study were 739 patients and 1,085 controls. According to evidence from observational studies, postmenopausal women who receive TSH suppression therapy are at risk for lower BMD. Long-term skeletal safety in DTC survivors should be prioritized.